Could a low-dose drug help relieve chronic fatigue and Long-COVID?

NCT ID NCT06257420

ENROLLING_BY_INVITATION Symptom relief Sponsor: Simmaron Research Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether low-dose rapamycin can reduce symptoms and improve quality of life in people with ME/CFS or Long-COVID. About 150 participants will take the drug as prescribed by their doctor and complete surveys and blood tests over time. The goal is to see if the drug helps with fatigue, daily function, and overall well-being.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID MYALGIC ENCEPHALOMYELITIS

Contacts and locations

Show contact details

Locations

Bateman Horne Center

Salt Lake City, Utah, 84102, United States
Center For Complex Diseases

Palo Alto, California, 94040, United States
Center For Complex Diseases

Seattle, Washington, 98109, United States
Sierra Internal Medicine

Incline Village, Nevada, 89451, United States
The Mayo Clinic

Rochester, Minnesota, 55905, United States